PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice.
Samuel K LeeRida A MalikJi ZhouWei WangPeter L GrossJeffrey I WeitzRithwik RamachandranBernardo L TrigattiPublished in: Arteriosclerosis, thrombosis, and vascular biology (2023)
The PAR4 inhibitory RAG8 pepducin reduced coronary artery atherosclerosis and myocardial fibrosis in SR-B1/LDLR double knockout mice fed a high-fat, high-cholesterol diet containing cholate. Furthermore, RAG8 reduced VCAM-1 in nonatherosclerotic coronary arteries and reduced leukocyte and platelet accumulation in atherosclerotic coronary arteries. These findings identify PAR4 as an attractive target in reducing coronary artery disease development, and the use of RAG8 may potentially be beneficial in cardiovascular disease.
Keyphrases
- coronary artery
- cardiovascular disease
- coronary artery disease
- pulmonary artery
- left ventricular
- cardiovascular events
- low density lipoprotein
- physical activity
- type diabetes
- percutaneous coronary intervention
- weight loss
- coronary artery bypass grafting
- heart failure
- blood flow
- acute coronary syndrome
- pulmonary hypertension
- cardiovascular risk factors
- liver fibrosis
- transcatheter aortic valve replacement